|
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 37589839 | Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. | Breast Cancer Res Treat | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 36892847 | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 36087190 | Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. | Breast Cancer Research and Treatment | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 34714340 | Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database. | JAMA Netw Open | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34117261 | Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. | npj Breast Cancer | 2021 |
| 33175437 | Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. | Cancer | 2021 |
| 33119476 | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. | J Clin Oncol | 2020 |
| 32259783 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32097092 | TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial). | J Clin Oncol | 2020 |
| 32550652 | The Project Baseline Health Study: a step towards a broader mission to map human health. | NPJ Digit Med | 2020 |
| 32798689 | TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. | Ann Oncol | 2020 |
| 32573935 | Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. | | 2020 |
| 30939096 | Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. | J Clin Oncol | 2019 |
| 31675952 | A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. | BMC Cancer | 2019 |
| 30553719 | Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. | J Geriatr Oncol | 2019 |
| 30328048 | Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. | Breast Cancer Res Treat | 2019 |
| 30635338 | Vaccine-Induced Memory CD8 T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. | Clinical Cancer Research | 2019 |
| 31120575 | The effect of treatment on patient-reported distress after breast cancer diagnosis. | Cancer | 2019 |
| 31005647 | Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool. | Journal of Geriatric Oncology | 2019 |
| 30787125 | NCCN Guidelines Insights: Breast Cancer, Version 3.2018. | J Natl Compr Canc Netw | 2019 |
| 30672045 | Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer. | J Magn Reson Imaging | 2019 |
| 30994574 | Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. | Menopause | 2019 |
| 29153866 | A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. | Clin Breast Cancer | 2018 |
| 29045554 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. | Ann Oncol | 2018 |
| 29992418 | Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. | Breast Cancer Res Treat | 2018 |
| 29523670 | Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29615305 | Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. | Clin Breast Cancer | 2018 |
| 28181348 | Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? | J Magn Reson Imaging | 2017 |
| 28404755 | NCCN Guidelines Insights: Breast Cancer, Version 1.2017. | J Natl Compr Canc Netw | 2017 |
| 27265406 | Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. | J Genet Couns | 2017 |
| 28064383 | Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. | Breast Cancer Res Treat | 2017 |
| 27768598 | Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. | Oncotarget | 2016 |
| 26957618 | Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2016 |
| 26850485 | Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. | J Natl Compr Canc Netw | 2016 |
| 26539793 | Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. | JAMA Oncol | 2016 |
| 27496115 | Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures. | Journal of the National Comprehensive Cancer Network : JNCCN | 2016 |
| 24836519 | The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. | J Biopharm Stat | 2015 |
| 25833335 | Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance. | J Genet Couns | 2015 |
| 25325325 | Can breast cancer molecular subtype help to select patients for preoperative MR imaging? | Radiology | 2015 |
| 25870381 | Breast Cancer Version 2.2015. | J Natl Compr Canc Netw | 2015 |
| 25777094 | Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer. | Annals of Surgical Oncology | 2015 |
| 25524311 | Circulating tumor cell analysis in metastatic triple-negative breast cancers. | Clinical Cancer Research | 2015 |
| 25564897 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. | N Engl J Med | 2015 |
| 26141457 | Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. | Breast Cancer Research | 2015 |
| 26656517 | NCCN Guidelines Insights Breast Cancer, Version 1.2016. | J Natl Compr Canc Netw | 2015 |